Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, operates in the healthcare industry, specifically in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system at the level of C3, the central protein in the complement cascade. The company's main business activities revolve around the development and commercialization of its lead product, pegcetacoplan, which is formulated for both intravitreal and systemic administration.

Apellis Pharmaceuticals generates revenue primarily from the sales of its lead product, pegcetacoplan. This product is approved for the treatment of geographic atrophy secondary to age-related macular degeneration (AMD) and paroxysmal nocturnal hemoglobinuria (PNH). The company has submitted marketing applications for pegcetacoplan to regulatory authorities in several countries, including the United States, European Union, Canada, Australia, the United Kingdom, and Switzerland. Moreover, the company's product pipeline includes EMPAVELI, which is used to treat PNH. The company's customer base includes patients with geographic atrophy secondary to AMD and PNH, as well as retina specialists and ophthalmologists.

Apellis Pharmaceuticals holds a competitive advantage over its competitors through its lead product, pegcetacoplan, which has been shown to be effective in treating geographic atrophy secondary to AMD and PNH. The company boasts a robust clinical profile, which has been demonstrated in several clinical trials. In terms of customer relationships, Apellis Pharmaceuticals' commercial organization is focused on building relationships with its customers and providing them with education and support to help them understand the benefits of pegcetacoplan and how to use it effectively. The company's key competitors include other biopharmaceutical companies that are developing treatments for geographic atrophy secondary to AMD and PNH, such as Novartis and Biogen.

The company's Ophthalmology segment is focused on the development and commercialization of pegcetacoplan for the treatment of geographic atrophy secondary to AMD. This segment includes the company's Phase 3 clinical trials, DERBY and OAKS, which evaluated the efficacy and safety of pegcetacoplan in patients with geographic atrophy secondary to AMD. The Rare Disease segment is focused on the development and commercialization of pegcetacoplan for the treatment of PNH. This segment includes the company's Phase 3 clinical trials, PRINCE and PEGASUS, which evaluated the efficacy and safety of pegcetacoplan in patients with PNH.

Apellis Pharmaceuticals' product portfolio includes pegcetacoplan, which is used to treat geographic atrophy secondary to AMD and PNH, and EMPAVELI, which is used to treat PNH. The company's intellectual property portfolio includes patents and patent applications covering its products and technologies. Additionally, the company has entered into licensing agreements with The Trustees of the University of Pennsylvania to develop and commercialize products covered by the licensed patent rights for all fields except the treatment of ophthalmic indications and for the treatment of ophthalmic indications.